Premium Under Pressure as Quality Lags
ISRG trades at a discount because margin and ROIC have slipped below peers. The market ignores innovation leadership when core returns weaken. For a medtech stock, 24.7% margin and 9.2% ROIC are not enough. Only a real margin recovery will change the story.
Published by AssetNext · 2026-07-19
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-07-17 | Profile and price weak | 33 | -41.7% | -29.8% |
Break down ISRG's structural position across all peer dimensions with the interactive app.